2021
Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)
Tisdale J, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, Pierciey F, Whitney D, Rogers C, Nnamani M, Foos M, Miller A, Zhang X, Lynch J, Walters M, Kanter J, Bonner M. Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood 2021, 138: 561. DOI: 10.1182/blood-2021-147760.Peer-Reviewed Original ResearchAcute myeloid leukemiaVaso-occlusive eventsCurrent equity holderSevere vaso-occlusive eventsGroup AGroup CMonth 6Clinical outcomesBluebird BioClinical benefitBusulfan conditioningCell doseRisk of AMLAutologous stem cell transplantTricuspid regurgitant jet velocityAdvisory CommitteeDriver mutationsLentiviral vectorsAML driver mutationsOpioid withdrawal syndromeSerious adverse eventsRegurgitant jet velocityFavorable clinical outcomeConsultancy feesStem cell transplant
2018
Platelet transfusion practices in immune thrombocytopenia related hospitalizations
Goel R, Chopra S, Tobian A, Ness P, Frank S, Cushing M, Vasovic L, Kaicker S, Takemoto C, Josephson C, Nellis M, Bussel J, Krishnamurti L. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion 2018, 59: 169-176. PMID: 30520045, DOI: 10.1111/trf.15069.Peer-Reviewed Original ResearchConceptsPlatelet transfusion practicesImmune thrombocytopeniaPlatelet transfusionsNational Inpatient SampleAdmission diagnosisTransfusion practiceCurrent guidelinesHigher mean total hospital chargesMean total hospital chargesSmall bed size hospitalsMultivariable logistic regression analysisPayer inpatient databasePrimary admission diagnosisSurgery/procedureTotal hospital chargesMajor operative proceduresLogistic regression analysisNon-teaching hospitalsInvasive surgical proceduresHospital mortalityMultivariable adjustmentITP patientsClinical outcomesRelated hospitalizationsHospital charges
2014
Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis
Wun T, Telen M, Krishnamurti L, McCavit T, DeCastro L, Flanner H, Kuypers F, Larkin S, Rhee S, Magnani J, Thackray H. Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. Blood 2014, 124: 2704. DOI: 10.1182/blood.v124.21.2704.2704.Peer-Reviewed Original ResearchSoluble E-selectin levelsPhase 2 trialVaso-occlusive crisisSE-selE-selectin levelsClinical outcomesAdhesion molecule-1Placebo groupLast doseSubgroup analysisE-selectinMolecule-1Sickle cell disease vaso-occlusive crisisDouble-blind phase 2 trialSoluble adhesion molecules E-selectinBaseline white blood cell countRandomized phase 2 studySCD vaso-occlusive crisisSoluble adhesion molecule concentrationsAge groupsVascular cell adhesion molecule-1White blood cell countIntercellular adhesion molecule-1Adhesion molecules E-selectinCell adhesion molecule-1A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease
Creary S, Gladwin M, Byrne M, Hildesheim M, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease. Pediatric Blood & Cancer 2014, 61: 1068-1073. PMID: 24436121, DOI: 10.1002/pbc.24931.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellAntisickling AgentsCell PhoneChildChild, PreschoolDirectly Observed TherapyDrug Administration ScheduleElectronic MailFeedbackFemaleHealth SurveysHumansHydroxyureaMaleMedication AdherenceMicrocomputersPatient SatisfactionPilot ProjectsReimbursement, IncentiveReminder SystemsRewardText MessagingVideo RecordingYoung AdultConceptsSickle cell diseaseMedian medication possession ratioMean corpuscular volumeHU adherenceHydroxyurea adherencePilot studyHemoglobin F percentageMedication possession ratioParticipant satisfactionPossession ratioSecondary outcomesPediatric patientsPrimary outcomeStudy entryClinical outcomesHU useHU therapyOverall participant satisfactionSingle institutionCell diseaseReminder alertsCorpuscular volumeTherapyAdherenceOverall median
2012
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe
Nouraie M, Lee J, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss T, Zeng Q, Kato G, Gibbs J, Hildesheim M, Sachdev V, Barst R, Machado R, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Goldsmith J, Gordeuk V, Gladwin M. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2012, 98: 464-472. PMID: 22983573, PMCID: PMC3659937, DOI: 10.3324/haematol.2012.068965.Peer-Reviewed Original ResearchConceptsRisk of deathSickle cell diseaseSickle cell anemiaClinical outcomesHemolytic componentPulse pressureCell diseaseOxygen saturationCell anemiaDirect markerRed blood cell microparticlesCutaneous leg ulcerationTricuspid regurgitation velocityIndependent risk factorCell-free hemoglobin concentrationsPulmonary systolic pressureVentricular diastolic dimensionSerum lactate dehydrogenaseSystemic pulse pressureLowest oxygen saturationTwo-year followHemoglobin SS patientsTotal bilirubin concentrationCertain clinical complicationsHigh hemoglobin F